ARV-102
-
Arvinas Presents Positive Phase 1 Data for PROTAC LRRK2 Degrader ARV-102 at 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas presented promising Phase 1 data for ARV-102, a brain-penetrant PROTAC LRRK2 degrader, at MDS 2025. ARV-102 was well-tolerated and demonstrated dose-dependent CSF exposure, indicating brain penetration. It achieved >90% PBMC LRRK2 reductions at ≥20mg. In healthy volunteers, 80mg for 14 days reduced CSF lysosomal and microglial markers linked to Parkinson’s disease. Multiple-dose patient data is expected in 2026, with a Phase 1b trial in progressive supranuclear palsy planned for H1 2026, pending IND clearance. The data supports further clinical development of ARV-102.
